MLYS
insider transactionsMineralys Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 30d
-26.0K
0 buy · 26.0K sell
Net value · 30d
-$631.2K
$0 in · $631.2K out
Sentiment · 30d
Net selling
0% buying · 100% selling
Open-market trades · 30d
5
0 buy · 26.0K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
417 sh
Own +13%
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
4.2K sh
Own +5%
-
Sell·S
Chief Medical Officer · 10b5-1
$114.6K
4.6K sh · $25.00
Own -7%
-
Exercise·M
Chief Medical Officer · 10b5-1
$6.4K
417 sh · $15.44
Own +1%
-
Exercise·M
Chief Medical Officer · 10b5-1
$59.4K
4.2K sh · $14.25
Own +7%
-
Exercise·M
Director · 10b5-1
$0
3.0K sh
Own +9%
-
Sell·S
Director · 10b5-1
$75.0K
3.0K sh · $25.00
Own -33%
-
Exercise·M
Director · 10b5-1
$36.1K
3.0K sh · $12.02
Own +48%
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
3.5K sh
Own +3%
-
Sell·S
Chief Medical Officer · 10b5-1
$235.5K
9.9K sh · $23.81
Own -15%
-
Exercise·M
Chief Medical Officer · 10b5-1
$36.1K
3.5K sh · $10.20
Own +6%
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
6.3K sh
Own New
-
Sell·S
Chief Medical Officer · 10b5-1
$151.9K
6.3K sh · $23.93
Own -9%
-
Exercise·M
Chief Medical Officer · 10b5-1
$6.9K
6.3K sh · $1.08
Own +10%
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
2.2K sh
Own +14%
-
Sell·S
Chief Medical Officer · 10b5-1
$54.2K
2.2K sh · $25.00
Own -3%
-
Exercise·M
Chief Medical Officer · 10b5-1
$34.7K
2.2K sh · $16.00
Own +3%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 17, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 417 | $0 |
| Jun 17, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 4.2K | $0 |
| Jun 17, 2026 | David Malcom Rodman 10b5-1 | Sell S | 4.6K | $114.6K |
| Jun 17, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 417 | $6.4K |
| Jun 17, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 4.2K | $59.4K |
| Jun 17, 2026 | Daphne Karydas 10b5-1 | Exercise M | 3.0K | $0 |
| Jun 17, 2026 | Daphne Karydas 10b5-1 | Sell S | 3.0K | $75.0K |
| Jun 17, 2026 | Daphne Karydas 10b5-1 | Exercise M | 3.0K | $36.1K |
| Jun 15, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 3.5K | $0 |
| Jun 15, 2026 | David Malcom Rodman 10b5-1 | Sell S | 9.9K | $235.5K |
| Jun 15, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 3.5K | $36.1K |
| Jun 12, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 6.3K | $0 |
| Jun 12, 2026 | David Malcom Rodman 10b5-1 | Sell S | 6.3K | $151.9K |
| Jun 12, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 6.3K | $6.9K |
| Jun 10, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 2.2K | $0 |
| Jun 10, 2026 | David Malcom Rodman 10b5-1 | Sell S | 2.2K | $54.2K |
| Jun 10, 2026 | David Malcom Rodman 10b5-1 | Exercise M | 2.2K | $34.7K |
About MLYS insider trading
This page tracks insider transactions for Mineralys Therapeutics, Inc. (MLYS) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.